Analysts Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $60.00

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $60.00.

Several research analysts recently issued reports on MNPR shares. Cantor Fitzgerald started coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They set an “overweight” rating and a $74.00 target price on the stock. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Monopar Therapeutics in a research note on Wednesday.

Monopar Therapeutics Stock Up 7.0%

MNPR opened at $35.86 on Tuesday. Monopar Therapeutics has a twelve month low of $2.15 and a twelve month high of $54.30. The company has a fifty day moving average of $38.04 and a 200-day moving average of $37.87. The stock has a market cap of $221.26 million, a PE ratio of -10.77 and a beta of 1.05.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12. Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 8,904 shares of the firm’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director directly owned 11,486 shares of the company’s stock, valued at approximately $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the firm’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares in the company, valued at $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,504 shares of company stock valued at $1,700,160. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MNPR. JPMorgan Chase & Co. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at $45,000. Geode Capital Management LLC grew its position in Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after purchasing an additional 24,530 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $13,182,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. Finally, Janus Henderson Group PLC bought a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $23,435,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.